Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE

The investigators conduct this clinical trial to evaluate the treatment outcome of RFA in HCC patients with tumor smaller than 7cm and tumor number less than five ,in comparison with TACE treatment.The primary outcome is overall survival.The secondary outcome is objective response rate.

Inclusion criteria:

• age 18 to 75 years ;
• HCC confirmed by pathological or clinical diagnosis according to the American Association for the Study of Liver Diseases criteria ;
• solitary HCC less than 7cm in diameter or multiple HCC lesions less 5
• the absence of portal/hepatic vein invasion, lymph node involvement and extrahepatic metastases;
• lesions visible on ultrasound with a safe path between the lesion and skin;
• an Eastern Cooperative Oncology Group performance status of 0-1;
• Child-Pugh class A or B cirrhosis.

The exclusion criteria :

• received any other previous treatment for HCC;
• severe coagulation disorders;
• evidence of hepatic decompensation including hepatic encephalopathy, ascites as well as esophageal or gastric variceal bleeding;
• presence of serious medical comorbidities, including serious dysfunction of the heart or kidney ;
• currently had other malignancies in addition to HCC.

No plan to make IPDavailable to other researchers